In this study, researchers investigated the healing effect of 1α-hydroxyvitamin D3 on the benign paroxysmal positional vertigo (BPPV). This is a kind of clinically common peripheral vestibular disease, which has the highest incidence rate in vertigo derived from the inner ear. Its main manifestation is that the transient paroxysmal vertigo can be caused when the head moves to a specific position, accompanied by nystagmus and autonomic neural symptoms.

In this study, 50 BPPV patients and 50 BBPV controls were selected, and the changes in bone metabolic markers, such as bone alkaline phosphatase (BALP), osteocalcin N-terminal middle molecular fragment (N-MID) and β-collagen degradation product (β-CTX), and BMD value in patients and control group before and after treatment with 1α-hydroxyvitamin D3 were detected, to provide a reference for the evaluation of curative effect of BPPV.

BPPV is a kind of common labyrinth disorder caused by the mechanical stimulation against the vestibular receptors in semicircular canal, whose typical features are positional vertigo and positional nystagmus, caused by changes in head position relative to the gravity. In most patients, it is easy to be diagnosed, and the treatment effect is very satisfactory for patients and physicians.

However, some cases are challenging in differential diagnosis, and the treatment effect on these cases is often poor. BPPV is the most common cause of vertigo in adults, and its incidence rate in normal population can be as high as approximately 10%. The right posterior semicircular canal is 1.5 times of the left posterior semicircular canal, which is associated with the right-side sleeping of most people.

BPPV is also known as ‘otolithiasis’. Otolith is an important organ to control the body's balance, and the normal otoliths are in the three semicircular canals. It was found in this study that the proportion of osteopenia/osteoporosis in female BPPV patients aged above 50 years was significantly higher than that in female patients aged below 50 years, and the BMD of patients could be effectively improved after treatment with 1α-hydroxyvitamin D3.

The BMD t-value in treatment group showed a decreasing trend with the increase of age. The levels of 25-hydroxyvitamin D3 and bone metabolic markers in treatment group were significantly improved compared with those before treatment (P<0.05).

Logistic regression analysis suggested that the level of 25-hydroxyvitamin D3 in patients is the clinical features indicating whether the treatment of BPPV is effective (P<0.05), and osteopenia/osteoporosis is also the clinical feature indicating whether the treatment of BPPV is effective (P<0.05). This is basically consistent with the research results in literature of others is.

In conclusion, the treatment of BPPV with 1α-hydroxyvitamin D3 can effectively improve the symptoms of patients, and the level of vitamin D3 and the occurrence of osteopenia/osteoporosis are the clinical indexes indicating whether the BPPV treatment is effective.